1. Zelenetz AD, Gordon LI, Wierda WG Abramson JS, et al. Non-Hodgkin’s lymphomas. Version 4.2014. In: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). National comprehensive cancer network; 2014. https://www.nccn.org/about/nhl.pdf . Accessed 20 Jun 2016.
2. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK, editors. SEER cancer statistics review, 1975–2012, National Cancer Institute. http://seer.cancer.gov/csr/1975_2012/ .
3. Zappasodi R, de Braud F, Di Nicola M, Koeck S, Zwierzina M, Huber JM, et al. Lymphoma immunotherapy: current status. Front Immunol. 2015;6:448.
4. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.
5. Baio FE, Kwak LW, Weng J. Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes. Am J Blood Res. 2014;4:46–52.